Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35,499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, Cigliola A, Tateo V, Patanè D, Grass GD, Gilbert SM, Sexton WJ, Bandini M, Moschini M, Briganti A, Montorsi F, Spiess PE, Necchi A. Li R, et al. Eur Urol Oncol. 2024 Jun;7(3):614-624. doi: 10.1016/j.euo.2023.12.008. Epub 2024 Jan 6. Eur Urol Oncol. 2024. PMID: 38184473
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma.
Huelster HL, Gould B, Schiftan EA, Camperlengo L, Davaro F, Rose KM, Soupir AC, Jia S, Zheng T, Sexton WJ, Pow-Sang J, Spiess PE, Daniel Grass G, Wang L, Wang X, Vosoughi A, Necchi A, Meeks JJ, Faltas BM, Du P, Li R. Huelster HL, et al. Among authors: li r. Eur Urol. 2024 Mar;85(3):283-292. doi: 10.1016/j.eururo.2023.09.017. Epub 2023 Oct 4. Eur Urol. 2024. PMID: 37802683
The Elusive Horizon: Biomarkers in Urothelial Carcinoma.
Linscott JA, Meeks JJ, Dyrskjøt L, Li R. Linscott JA, et al. Among authors: li r. Eur Urol. 2024 Apr;85(4):317-319. doi: 10.1016/j.eururo.2024.01.004. Epub 2024 Jan 25. Eur Urol. 2024. PMID: 38278663
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.
Li R, Hensley PJ, Gupta S, Al-Ahmadie H, Babjuk M, Black PC, Brausi M, Bree KK, Fernández MI, Guo CC, Horowitz A, Lamm DL, Lerner SP, Lotan Y, Mariappan P, McConkey D, Mertens LS, Mir C, Ross JS, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess PE, Svatek RS, Tan WS, Taoka R, Buckley R, Kamat AM. Li R, et al. Eur Urol. 2024 Dec;86(6):516-527. doi: 10.1016/j.eururo.2024.08.001. Epub 2024 Aug 24. Eur Urol. 2024. PMID: 39183090 Review.
FGFR Inhibition in Urothelial Carcinoma.
Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS, van der Heijden MS, van Rhijn BWG, Loriot Y. Li R, et al. Eur Urol. 2024 Sep 30:S0302-2838(24)02605-8. doi: 10.1016/j.eururo.2024.09.012. Online ahead of print. Eur Urol. 2024. PMID: 39353825 Review.
Re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027.
Guske C, Jazayeri SB, Li R. Guske C, et al. Among authors: li r. Eur Urol. 2024 Oct 14:S0302-2838(24)02638-1. doi: 10.1016/j.eururo.2024.09.034. Online ahead of print. Eur Urol. 2024. PMID: 39406614 No abstract available.
Reply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.06.011.
Tan WS, O'Donnell M, Li R, Kamat AM, Packiam VT. Tan WS, et al. Among authors: li r. Eur Urol Oncol. 2023 Oct 26:S2588-9311(23)00225-0. doi: 10.1016/j.euo.2023.10.009. Online ahead of print. Eur Urol Oncol. 2023. PMID: 39492318 No abstract available.
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer.
Taylor J, Kamat AM, Annapureddy D, Khene ZE, Howard J, Tan WS, McElree IM, Facundo D, Yim K, Harrington S, Dyer E, Black AJ, Kanabur P, Roumiguié M, Lerner S, Black PC, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam VT, Woldu SL, Lotan Y, O'Donnell MA. Taylor J, et al. Among authors: li r. Eur Urol Oncol. 2024 Dec 17:S2588-9311(24)00288-8. doi: 10.1016/j.euo.2024.12.005. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39694798
The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: Results from the upper tract collaborative network (UCAN).
Carpinito GP, Gerald T, Hensley PJ, Martin AJ, Pallauf M, Pham J, Li R, Potretzke AM, Spiess PE, Singla N, Raman JD, Coleman J, Matin SF, Margulis V. Carpinito GP, et al. Among authors: li r. Urol Oncol. 2024 Dec 24:S1078-1439(24)00774-9. doi: 10.1016/j.urolonc.2024.11.025. Online ahead of print. Urol Oncol. 2024. PMID: 39721824
35,499 results
You have reached the last available page of results. Please see the User Guide for more information.